60
Participants
Start Date
February 6, 2014
Primary Completion Date
April 30, 2018
Study Completion Date
April 30, 2018
Midostaurin
Midostaurin was supplied in 25mg soft gelatin capsule taken orally twice a day for 28 days of each cycle. Patients will be treated for 12 cycles.
Standard of Care
Standard of Care was not defined per protocol. The investigator prescribed based on the commonly used medications given in the post SCT setting.
Northside Hospital, Atlanta
H Lee Moffitt Cancer Center and Research Institute Oncology, Tampa
Tennessee Oncology Sarah Cannon Research Inst., Nashville
Vanderbilt Univeristy Oncology, Nashville
University Hospitals Case Medical Center, Cleveland
Karmanos Cancer Institute Karmanos - Wayne State, Detroit
Mayo Clinic - Rochester, Rochester
University of Chicago Medical Center, Chicago
Washington University School Of Medicine-Siteman Cancer Ctr Washington U School of Med, St Louis
Baylor Health Care System/Sammons Cancer Center Oncology, Dallas
Texas Transplant Physicians Group Oncology 2, San Antonio
SCRI- Colorado Blood Cancer Institute, Denver
University of California at Los Angeles Oncology, Los Angeles
Oregon Health Sciences University, Portland
Fred Hutchinson Cancer Research Center Oncology, Seattle
University of California San Diego Moores Cancer Center, La Jolla
Hackensack University Medical Center Hackensack Univ Med Ctr (32), Hackensack
University of North Carolina at Chapel Hill University of North Carolina 6, Chapel Hill
Novartis Investigative Site, Toronto
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY